Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for skull base cancers.

E M Diaz1, M S Kies

  • 1Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. ediaz@mdanderson.org

Otolaryngologic Clinics of North America
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis of hydroxyapatite-iron oxides nanocomposite for fluoride adsorption in groundwater samples.

Environmental geochemistry and health·2025
Same author

Synthesis of novel magnetic hydroxyapatite-biomass nanocomposite for arsenic and fluoride adsorption.

Environmental geochemistry and health·2024
Same author

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

This article reviews skull base cancer treatments, including nasopharyngeal carcinoma and esthesioneuroblastoma. Advances have reduced patient morbidity and improved survival rates for these challenging conditions.

Area of Science:

  • Oncology
  • Neurosurgery
  • Otolaryngology

Background:

  • Skull base tumors present complex treatment challenges.
  • Traditional treatments often involve significant morbidity.
  • Advances in surgical and oncologic therapies are crucial.

Purpose of the Study:

  • To review current treatment options for select skull base cancers.
  • To highlight therapeutic strategies that minimize post-treatment morbidity.
  • To discuss approaches that improve survival outcomes.

Main Methods:

  • Literature review of treatment modalities for specific skull base malignancies.
  • Analysis of outcomes data focusing on morbidity and survival.
  • Synthesis of evidence for nasopharyngeal carcinoma, sinonasal cancers, and others.

Related Experiment Videos

Main Results:

  • Selected treatment strategies have demonstrably decreased post-treatment morbidity.
  • Improved survival rates are achievable with modern therapeutic approaches.
  • Effective management encompasses a range of cancers including esthesioneuroblastoma and salivary gland carcinomas.

Conclusions:

  • Current treatment options for select skull base cancers offer improved outcomes.
  • Minimizing morbidity and maximizing survival are key goals in skull base oncology.
  • Continued research into advanced therapies is warranted.